排序方式: 共有6条查询结果,搜索用时 15 毫秒
1
1.
Gusbeth-Tatomir P Boisteanu D Seica A Buga C Covic A 《International urology and nephrology》2007,39(4):1217-1226
The prevalence of sleep disorders is significantly higher (up to 80%) in patients with chronic uremia compared to the general
population. Sleep disorders appear even in the early stages of chronic kidney disease. These disturbances are complex, including
difficulties in falling asleep and awakening, interrupted sleep, nightmares, restless legs syndrome, sleep apnea syndrome,
etc. There are still disagreements on the major etiological factors of sleep disorders in the uremic patient. Older age, long
dialysis vintage, alcohol and tobacco abuse and, particularly, the presence of significant comorbidities are major determinants
of sleep disorders in dialysis patients. Proper assessment of sleep disorders in the renal population is still under investigation;
recent studies have mostly addressed patients’ perception based on questionnaires. More precise polysomnographic assessments
are less studied in renal patients. Sleep disorders significantly affect quality of life in dialysis patients. An accurate
and early identification of such disturbances would lead to a significant improvement in quality of life, and probably also
in outcome, in uremic patients. Sleep apnea syndrome is extremely frequent in dialysis patients, with obvious consequences
for cardiovascular morbidity and mortality. Proper diagnosis and therapy of sleep apnea syndrome could significantly reduce
cardiovascular risk. Although sleep quality improves after renal transplantation, allograft recipients still have significantly
more sleep disorders than healthy individuals. Here, we review recent data on sleep disturbances in renal patients, focusing
on the end-stage renal disease patient treated by dialysis. 相似文献
2.
Costan Victor Vlad Ciocan-Pendefunda Constantin-Catalin Ciofu Mihai Liviu Boisteanu Otilia Timofte Daniel Vasile Gheorghe Liliana Bogdanici Camelia Preda Cristina 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(10):2313-2320
Graefe's Archive for Clinical and Experimental Ophthalmology - The purpose of this study is to share our experience on the use of different orbital decompression techniques, as well as the... 相似文献
3.
Ulmeanu Ruxandra Sabina Antonela Antoniu Florin Mihaltan Daniela Boisteanu 《Expert opinion on pharmacotherapy》2015,16(10):1539-1541
Introduction: In non-exacerbation chronic obstructive pulmonary disease (COPD) with mild lung function impairment, single bronchodilator therapy might be as effective as combined inhaled corticosteroid/bronchodilator therapy, whereas the risk of pneumonia associated with the latter would be practically absent.
Areas covered: We performed an analysis of a recent study evaluating the efficacy and safety of inhaled indacaterol versus inhaled salmeterol/fluticasone in COPD patients.
Expert opinion: Both therapies were found to exert comparable effects on lung function, symptom severity and health status. 相似文献
4.
5.
6.
Ion Haulica Walther Bild Christian Mihaila Dragomir N Serban Lacramioara Serban Daniela Boisteanu Teodor Ionita Oana Radasanu 《Journal of the renin-angiotensin-aldosterone system》2004,5(2):79-83
Adrenomedullin (ADM), a ubiquitous vasoactive peptide, has been the target of a multitude of studies concerning its effect on the vascular tone. The present work aims at clarifying a series of its interactions with the renin-angiotensin system. The study uses the rat aorta ring as a model of conductance vessels, with or without vascular endothelium, and the second order branch of rat mesenteric arteries as a model of resistance arteries. Interactions between various concentrations of ADM and angiotensin II (Ang II) were studied, in the presence of L-NAME (a nitric oxide [NO] synthase inhibitor) and methylene blue (MB; a soluble guanylate cyclase inhibitor). Results point out differences in the mechanism of the inhibitory action of ADM upon Ang II effects in the two vessel types studied. Inhibition of Ang II contraction by ADM involves guanylate cyclase in both cases. However, NO is involved in ADM-induced inhibition of angiotensinergic vasoconstriction only in the conductance arteries, not in the resistance ones. 相似文献
1